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Elevated Endothelin-1 in Intradialytic Hypertension
Abstract  Objective: To determine the relative change in endothelin-1 (ET-1) during 
hemodialysis procedure in Stage Five Dialysis-Dependent Chronic Kidney 
Disease (CKD-5D) patients with and without intradialytic hypertension 
(IDH).
 Methods: This was a cross-sectional, observational study involving 40 
CKD-5D patients who received two hemodialysis per week for at least three 
months at the dialysis unit of Dr. Hasan Sadikin Hospital General Bandung, 
Indonesia, during September 2016. Subjects were divided into two groups: 
with IDH (n=20) and without IDH (n=20). Plasma ET-1 level was examined 
before and after hemodialysis.  
 
 Results: There was a significant elevation of ET-1 level (mean±SD pg/mL) 
between pre- and post-dialysis states in patients with IDH (3.33±1.28 vs. 
3.84±1.75; relative changes: 15.32%, p=0.013). No change was observed 
in patients without IDH (3.99±2.30 vs. 4.38±1.81; relative changes: 9.77% 
p=0.083). The post-dialysis absolute ET-1 level was significantly lower in 
CKD-5D patients with IDH (3.84±1.75 vs. 4.38±1.81; p=0.024). 
 Conclusions: There was a significant elevation of ET-1 level in CKD-5D 
patients with IDH during the hemodialysis procedure at the dialysis unit of 
Dr. Hasan Sadikin General Hospital Bandung.
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Introduction
Hemodialysis is the main renal replacement 
therapy (RRT) option for patients with end-
stage kidney disease who cannot undergo 
renal transplantation. Although techniques 
in hemodialysis are advancing rapidly, 
intradialytic hypertension (IDH) is still one 
of the most poorly-recognized complications 
in patients receiving hemodialysis.1 IDH 
is associated with increased rates of 
hospitalization, poorer survival rate, and 
death in dialysis-dependent stage five chronic 
kidney disease patients (CKD-5D).2-5 IDH 
occurs in 10-12% hemodialysis patients. 3, 6
The pathogenesis of IDH in patients 
undergoing routine hemodialysis has not been 
fully understood. Many factors are considered 
to be the cause of this complication.2 Studies 
demonstrated that the endothelin-1 (ET-1) 
level significantly increases in IDH patients in 
comparison to controls.7-11 In a pathological 
condition, the ET-1 may induce endothelial 
dysfunction, increase peripheral resistance, 
and eventually lead to IDH.6,12 
A study in Bandung and a study by the 
Indonesian Renal Registry showed that 
IDH accounts for 35–36% of complications 
in hemodialysis patients.13,14 Furthermore, 
a study which included some hospitals in 
Bandung showed a different ratio from earlier 
studies in other countries.14 This raises the 
question of whether there are differences in 
the cause of high IDH incidence, particularly 
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in the ET-1 level as a marker of endothelial 
dysfunction. Previous studies determined 
the absolute changes of ET-1 before and after 
dialysis in patients with IDH and controls. 
Since many factors may contribute to the 
ET-1 baseline level alterations, a significant 
difference in plasma ET-1 may be found in 
patients with and without IDH. Hence, it is 
crucial to establish the relative change in the 
ET-1 level between the two groups during the 
hemodialysis procedure.
This study aimed to determine the relative 
change of ET-1 levels in the CKD-5D patients 
with and without IDH treated at the dialysis 
unit of Dr. Hasan Sadikin General Hospital 
Bandung, Indonesia.
Methods
This study was a cross-sectional observational 
study on CKD-5D patients who underwent 
routine hemodialysis twice a week for more 
than three months in Dr. Hasan Sadikin 
General Hospital Bandung, Indonesia, during 
September 2016. From the calculation using 
the formula below, a minimum of 16 subjects 
for the group with predictor (IDH) and 16 
subjects for the group without predictor 
(without IDH) were required. The alpha 
standard deviation was 5%; therefore, the Zα/2 was 1.96, and the beta standard deviation was 
10%. Hence, the Zβ would be 1.28.
A consecutive sampling technique was 
applied for subject recruitment. Patients 
were categorized into the group with IDH 
(n=20) or without IDH (n=20). The inclusion 
criteria were adult patients aged 18 years old 
or older who took anti-hypertensive drugs. 
Patients who had atrial fibrillation or whose 
blood pressure (BP) could not be measured by 
standard procedures were excluded. 
Patients’ blood pressure was measured 
before and after each hemodialysis session. 
IDH was defined as a difference in systolic 
BP (post-dialytic BP minus pre-dialytic 
BP) of more than 10 mmHg, with a BP of 
above 130/80 mmHg after completing the 
hemodialysis session. 1,3 Patient’ body weight 
was measured before and after hemodialysis 
sessions.  The IDWG was calculated as pre-
dialysis weight minus post-dialysis weight 
of the previous hemodialysis session. 15 The 
ultrafiltration rate was defined by dividing 
the ultrafiltration volume (ml) by the length of 
time of the dialysis session (hours) and target 
dry weight (kg).16
The difference in ET-1 level between the 
pre- and post-dialysis was evaluated by using 
the paired T-test. while the comparison of 
ET-1 level and their changes between IDH and 
non-IDH groups were performed using the 
unpaired T-test.  P-value <0.05 was considered 
statistically significant. 
The ethical clearance for this study was 
obtained from the Ethics Committee of the 
Faculty of Medicine of Universitas Padjadjaran 
under the ethical clearance number: LB.04.0l/
AO5/EC/250/Vll/2016.
Results 
A total of 40 subjects were included in the 
study, with twenty subjects for each group.
Table 1 presents the baseline characteristics of 
the study subjects. Other than the interdialytic 
weight gain (IDWG), ultrafiltration, and history 
of hypertension in the last one month, the 
baseline characteristics between the CKD-5D 
patients with and without IDH were similar.  
In subjects with IDH, the mean age was 
54±12 years old. The mean pre-dialytic and 
post-dialytic BP in this group were 160/79 
mmHg and 186/89 mmHg, respectively, while 
the mean dry body weight was 50.2±10.6 kg.  
The mean IDWG was significantly higher 
(p=0.048) in subjects without IDH, with 80% 
(n=16) of patients experiencing an increase in 
IDWG. The mean ultrafiltration volume was 
also significantly higher (p=0.009) in subjects 
without IDH. 
On pulse pressure and pulse rate 
examination, the mean values between 
subjects with and without IDH were similar 
(81±20 mmHg versus 75±25 mmHg and 
75±10 times per minute versus 81±11 75. 
respectively). The hematocrit and sodium 
levels were also found to be similar between 
the two groups.      
Based on the diagnosis of CKD, 
hypertension was the most common cause 
(65%) in subjects with intradialytic group, 
followed by diabetic kidney disease (25%), 
primary glomerulopathy (5%), and lupus 
nephritis (5%). Whereas, in the group without 
IDH, the most common cause of CKD was 
hypertension (55%), followed by diabetic 
kidney disease (25%), PNC (10%), and 
primary glomerulopathy (10%).
The history of IDH in the last one month 
was significantly higher (p=0.034) in subjects 
with IDH, occurring 2–9 times a month.
Table 2 shows the ET-1 level in the study 
subjects before and after dialysis. In the IDH 
group, the mean (±SD) of pre-dialytic and 
post-dialytic ET-1 level was 3.33±1.28 pg/mL 
and 3.84±1.75 pg/mL, respectively, and the 
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Table 1 Baseline Characteristics 
Variable IDH(n =20)
Without IDH
 (n =20) P-value
Age (years)




















(median (min-max)) 24 (3 – 77) 27 (3 – 87) 0.797‡
Dry Weight






















































































History of IDH in the last one month
(median (min-max)) 4 (2 – 9) 3 (1 – 5) 0.034‡¶
SD: standard deviation; ESA: Erythropoietin Stimulating Agents; analysis was performed using *T-test, †Chi Square, 
‡Mann Whitney, §Fisher Exact, ¶statistically significant (p<0.05); IDWG = Interdialytic Weight Gain
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mean absolute change of the ET-1 level in this 
group was 0.51 pg/mL (95% CI: 0.07–0.96 pg/
mL), with a relative change of 15.32% (95% 
CI: -6.19–19.17%). The mean absolute change 
of post-dialytic ET-1 level was significantly 
higher when compared to the pre-dialytic 
level (p=0.013), but the relative change was 
not significantly altered (p>0.05).
In the CKD-5D patients without IDH, the 
mean (± SD) pre-dialytic ET-1 level was 
3.99±2.30 pg/mL, while the post-dialytic level 
was 4.38±1.81 pg/mL. The mean absolute 
change of the ET-1 level in this group was 
0.39 pg/mL (95% CI: -0.18–0.97 pg/mL), and 
the relative change was 9.77% (95% CI: 6.25–
36.72%). However, neither absolute change 
nor relative change of ET-1 level differed 
significantly between pre and post-dialysis 
(p=0.083) groups.
The pre-dialytic ET-1 level was not 
significantly different between subjects with 
IDH and without IDH. In the post-dialytic 
state, a significantly higher ET-1 level in the 
IDH group was observed (p=0.024). However, 
the absolute and relative changes were not 
significantly different.
Discussion 
In this study, the subjects’ mean age was 
slightly higher in those with IDH when 
compared to the subjects without IDH, 
although no significant mean age difference 
was identified between the two groups. Inrig et 
al. previously presented that IDH is commonly 
found in elderly CKD subjects who had routine 
hemodialysis. Endothelial dysfunction in 
elderly patients was thought to be a risk factor 
for IDH.3 
The mean dry weight of subjects with IDH 











Mean±SD Mean±SD Mean(95% CI)
Mean
(95% CI)




Without IDH 3.99±2.30 4.38±1.81 0.39(-0.18–0.97)
9.77
(-6.19–19.17) 0.083
p-value† 0.135 0.024‡ 0.367 0.293
SD: Standard Deviation; CI: Confidence Interval; analysis were performed using *Paired t-test, †Independent t-test, 
‡statistically significant (p<0.05)
Fig. Absolute Change of ET-1 Level Before and After Dialysis
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was lower than that of subjects without IDH. 
This result was in accordance with a previous 
study by Van Buren et al., although both studies 
showed no significant difference between the 
two groups.6
This study demonstrated that the absolute 
values of IDWG and ultrafiltration were 
significantly lower in subjects with IDH, albeit 
this was not the case in the relative change. 
The IDWG and ultrafiltration have been 
proposed to be involved in the pathogenesis of 
IDH. Patients with IDH had lower body weight, 
smaller IDWG, and slower ultrafiltration rates. 
IDH patients tend to gain less weight between 
procedures, making it necessary to prescribe 
slower ultrafiltration. The smaller the 
ultrafiltration rate, the less volume depletion 
occurs. This condition promotes IDH. 2, 6
The absolute value of IDWG and 
ultrafiltration in subjects with IDH was 
significantly lower. This result was similar to 
previous data.4,6,17 However, a contradicting 
result from a recent large cohort study showing 
that the higher the IDWG, both absolute and 
relative, the more frequent the intradialytic 
event is.18 Therefore, the relation between 
IDWG and intradialytic blood pressure is 
still controversial. Lopez et al. stated that 
excessive IDWG is a sign of excess sodium 
level and water, which could cause fluid 
overload. This might contribute to arterial 
hypertension in CKD patients undergoing 
routine hemodialysis. 19 Other studies found 
that hypervolemia and body weight have no 
effect on systolic and diastolic blood pressures 
in patients with routine hemodialysis   and 
that there is no direct association between 
IDWG and blood pressure in dialysis patients. 
20, 21 Of the few previous studies, no conclusive 
evidence can be drawn. This is likely due to the 
complexity of hypertension pathophysiology.
In this study, the post-dialysis ET-1 level 
was higher in patients without IDH.  However, 
the pre-dialysis level of ET-1 was similar in 
patients with or without IDH. This was in 
accordance with earlier studies.8,10hematocrit 
(Hct However, in contrary to this study, 
previous studies demonstrated that the post-
dialysis ET-1 level is significantly higher in 
patients with IDH.8, 10 
This discordance may be partially explained 
by the higher absolute values of IDWG and 
ultrafiltration in patients without IDH in this 
study. As it is previously mentioned, one large 
cohort study associated the increase in IDWG 
and ultrafiltration with a greater IDH incidence. 
In addition, ultrafiltration is shown to affect 
the ET-1 release in hemodialysis patients.22 
In this study, a greater ultrafiltration absolute 
value found in patients without IDH may cause 
a higher ET-1 outcome. The increase in ET-1 
levels was not only observed in the patients 
with IDH but also in patients without IDH.
Another plausible explanation is the 
discrepancy in the absolute ET-1 values across 
studies. Although using the same reagent 
(R&D System Inc., Minneapolis, MN, USA), the 
ET-1 levels obtained vary widely. Chou et al. 
found a much higher average level of ET-1. 
(510.9±43.3 vs. 276.7±30.1 pg/ml in subjects 
with and without IDH, respectively).8 While 
Teng et al. (4.09±2.06 vs. 2.75±1.34 pg/mL) 
showed similar values  to this study.10 This 
might be influenced by different sampling 
techniques or racial factors, which had not 
been well studied.
A significant ET-1 level elevation was 
demonstrated in patients with IDH in this 
study; however, no significant alteration was 
seen in patients without IDH. The absolute 
change was also significantly elevated, but 
this was not the case in the relative change of 
the ET-1 level. This is parallel with previous 
research, which revealed a significant elevation 
of ET-1 level in the IDH group albeit no change 
was observed in the control group.8, 10 These 
results indicate a relationship between IDH 
incidence and ET-1 level.
There are limitations to this study. The 
sampling was performed consecutively, not 
randomly. In addition, the dry weight was only 
measured clinically, and no accurate tool with 
the ability to measure the volume of fluid in 
the body (multiple frequency bioimpedance 
spectroscopy) was used. 
In summary, there is a significant elevation 
of the ET-1 level in CKD-5D patients with IDH 
during the hemodialysis procedure. However, 
no CKD-5D patients in this study population, 
both with and without IDH, experience a 
relative change in the ET-1 level. A cohort study 
is needed in patients with elevated ET-1 levels 
to evaluate the incidence of subsequent IDH in 
order to assess whether ET-1 levels can predict 
an IDH event. Furthermore, a comprehensive 
multivariate study is needed to establish the 
relationship between risk factors for IDH, both 
for clinical and biochemical risk factors.
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